IP Library Patent Application 14873296
Patent Application
App. No. 14/873,296

CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/873,296
Abstract

Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.

Claims (27)

1 .- 55 . (canceled)

56 . A fusion protein, comprising:

a. a protein transduction domain of a Tat protein; and

b. a MYC protein that is attached to the protein transduction domain of the Tat protein,

wherein the fusion protein has MYC activity.

57 . The fusion protein of claim 56 , wherein the Tat protein is HIV-1 Tat.

58 . The fusion protein of claim 56 , wherein the MYC protein is capable of promoting in vitro cell proliferation, cell survival, or both.

59 . The fusion protein of claim 56 , wherein the MYC protein comprises the amino acid sequence of SEQ ID NO: 2.

60 . A composition comprising:

a. the fusion protein of claim 56 ; and

b. a fusion protein comprising a Bcl-2 family member that inhibits apoptosis, and

the protein transduction domain of a Tat protein.

61 . The composition of claim 59 , wherein the Bcl-2 family member is Bcl-2.

62 . The composition of claim 61 , wherein Bcl-2 comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 8.

63 . A method for promoting one or more of cell proliferation or cell survival of one or more cells cultured in vitro comprising:

providing to the one or more cells the fusion protein of claim 56 ; and culturing the one or more cells in a media.

64 . The method of claim 63 , wherein the culturing promotes in vitro cell proliferation, cell survival, or both; and wherein one or more of the survival or proliferation of the one or more cells is increased as compared with corresponding cells not exposed to the fusion protein or to the composition.

65 . The method of claim 63 , wherein the one or more cells are immune cells.

66 . The method of claim 65 , wherein the one or more immune cells are activated immune cells.

67 . The method of claim 66 , wherein the one or more immune cells are T cells.

68 . The method of claim 66 , wherein the one or more immune cells are B cells.

69 . The method of claim 66 , wherein the one or more immune cells are NK cells.

70 . The method of claim 63 , wherein the one or more cells are stem cells.

71 . The method of claim 70 , wherein the one or more stem cells are hematopoietic stem cells.

72 . The method of claim 70 , wherein the one or more stem cells are human stem cells.

73 . The method of claim 70 , wherein the one or more stem cells are genetically modified.

74 . A method for promoting one or more of cell proliferation or cell survival of one or more cells cultured in vitro comprising: providing to the one or more cells the composition of claim 60 ; and culturing the one or more cells in a media.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2024
From: TAIGA BIOTECHNOLOGIES, INC.
To: TAIGA BIOTECHNOLOGIES (ABC), LLC
Reel/Frame 066186/0624 →